Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2026 02:00 ET | Source: Directed Technologies

Directed Technologies Expands Global Connected Vehicle Platform into Africa through Strategic Partnership with 3Gen Products

MELBOURNE, Australia and JOHANNESBURG, April 28, 2026 (GLOBE NEWSWIRE) -- Directed Technologies has announced a strategic partnership with 3Gen Products to extend its global, OEM-aligned connected...
April 28, 2026 02:00 ET | Source: Serabi Gold plc

Results of Updated Mineral Resource and Reserves; Increases Consolidated M&I to 731koz Au and Inferred Resource to 653koz Au

Results of Updated Mineral Resource and Reserves; Increases Consolidated M&I to 731koz Au and Inferred Resource to 653koz Au Serabi Gold plc (“Serabi” or the “Company”) (AIM:SRB, TSX:SBI,...
April 28, 2026 02:00 ET | Source: AdJane

CARB-X awards funding to AdJane to advance its nOMV platform-derived vaccine for the prevention of gonorrhea

CARB-X awards funding to AdJane to advance its nOMV platform-derived vaccine for the prevention of gonorrhea.
April 28, 2026 02:00 ET | Source: Ekspress Grupp

Aktsiaseltsi Ekspress Grupp korralise üldkoosoleku kokkukutsumise teade

Aktsiaseltsi Ekspress Grupp (registrikood 10004677, asukoht Narva mnt 13, 10151 Tallinn, „Ekspress Grupp“) juhatus kutsub kokku aktsionäride korralise üldkoosoleku, mis toimub 1. juunil 2026. aastal...
April 28, 2026 02:00 ET | Source: Elis S.A.

Elis: Disclosure of trading in own shares occured from April 20 to April 24, 2026

Disclosure of trading in own shares occurred from April 20 to April 24, 2026 Puteaux, April 28, 2026 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052,...
April 28, 2026 02:00 ET | Source: Scancell Holdings Plc

Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study

Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, demonstrated in the Phase 2 SCOPE trial; more PFS and...
April 28, 2026 02:00 ET | Source: Ålandsbanken

Ålandsbanken Abp: Delårsrapport för perioden januari–mars 2026

Ålandsbanken AbpDelårsrapport28.4.2026 kl. 9.00 EEST Delårsrapport för perioden januari–mars 2026 Stabil utveckling i ett mer osäkert omvärldsläge Ålandsbanken levererar under årets första...
April 28, 2026 02:00 ET | Source: Ålandsbanken

Bank of Åland Plc: Interim Report for the period January - March 2026

Bank of Åland PlcInterim ReportApril 28, 2026 9.00 EEST Interim Report for the period January - March 2026 Stable development in a more uncertain operating environment “In the first quarter, the...
April 28, 2026 02:00 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial

In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1The trial met both weight...
April 28, 2026 02:00 ET | Source: NB Private Equity Partners Limited

NBPE Announces Transaction in Own Shares

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS NB...